Patents Examined by Brad Duffy
-
Patent number: 9938351Abstract: This invention provides a composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a suitable carrier. This invention provides a pharmaceutical composition comprising an effective amount of monoclonal antibody 8H9 or a derivative thereof and a pharmaceutically acceptable carrier. This invention also provides an antibody other than the monoclonal antibody 8H9 comprising the complementary determining regions of monoclonal antibody 8H9 or a derivative thereof, capable of binding to the same antigen as the monoclonal antibody 8H9. This invention provides a substance capable of competitively inhibiting the binding of monoclonal antibody 8H9. This invention also provides an isolated scFv of monoclonal antibody 8H9 or a derivative thereof. This invention also provides the 8H9 antigen.Type: GrantFiled: November 30, 2016Date of Patent: April 10, 2018Assignee: Sloan-Kettering Institute for Cancer ResearchInventor: Nai-Kong V. Cheung
-
Patent number: 9932411Abstract: The invention provides antibodies which bind to the extracellular domain of the Tyrosine-protein kinase transmembrane receptor Matriptase. Nucleic acid molecules encoding the antibodies, expression vectors, host cells and methods for expressing the antibodies are also provided. The antibodies may be used for the treatment of cancer, including gastric cancer, colorectal cancer, prostate cancer, breast cancer, ovarian cancer lung cancer, preferably SCLC, esophageal cancer, head and neck cancer, pancreatic cancer, lymphoma preferably non-Hodgkin's lymphoma and skin cancer.Type: GrantFiled: November 25, 2014Date of Patent: April 3, 2018Assignee: Oxford BioTherapeutics LtdInventors: Jonathan Alexander Terrett, Chetana Rao-Naik, Haichun Huang, Sarah Pogue, Erika Meaddough, Michelle Kuhne, Chin Pan
-
Patent number: 9926364Abstract: Provided are chimeric, camelid-human (e.g., llama-human) polypeptides comprising a first antigenic polypeptide portion and a second antigenic polypeptide portion wherein the first antigenic portion is a derived from a first portion of a camelid (e.g., llama) and the second antigenic portion is a human polypeptide homolog of a second portion of the camedid antigen. The chimeric polypeptides are useful inter alia for epitope mapping and generation of antibodies that bind to a desired region of human antigen.Type: GrantFiled: November 5, 2012Date of Patent: March 27, 2018Assignee: ARGEN-X N.V.Inventors: Johannes Joseph Wilhelmus De Haard, Natalie De Jonge, Anna Hultberg, Christophe Blanchetot, Karen Silence, Peter Ulrichts, Torsten Dreier
-
Patent number: 9919061Abstract: This invention relates to CD19 binding agents and methods of using such CD19 binding agents for treating disease.Type: GrantFiled: June 18, 2015Date of Patent: March 20, 2018Assignee: SEATTLE GENETICS, INC.Inventors: Charlotte McDonagh, Charles G. Cerveny, Dennis Benjamin, Paul Carter
-
Patent number: 9914777Abstract: The invention is among others concerned with human CD3 binding antibodies comprising a heavy chain and light chain wherein said heavy chain comprises a variable region that comprises the amino acid sequence (SEQ ID NO: 61): QVQLV QSGGG VVQPG RSLRL SCVAS GFTFS SYGMH WVRQA PGKGL EWVAA IWYX1X2 RKQDY ADSVK GRFTI SRDNS KNTLY LQMNS LRAED TAVYY CTRGT GYNWF DPWGQ GTLVT VSS with 0-5 amino acid insertions, deletions, substitutions, additions or a combination thereof at one or more positions other than the position indicated by X1X2; wherein X1=N and X2=A; X1=N and X2=T; X1=S and X2=G; X1=H and X2=G; X1=D and X2=G; or X1=H and X2=A. The invention is also concerned with bispecific antibodies that have a heavy chain as defined herein above. The invention is also concerned with methods of production of the antibody, cells producing the antibody and with (medical) uses of the antibody.Type: GrantFiled: July 8, 2016Date of Patent: March 13, 2018Assignee: Merus N.V.Inventors: Alexander Berthold Hendrik Bakker, Pieter Fokko Van Loo
-
Patent number: 9890204Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.Type: GrantFiled: August 7, 2012Date of Patent: February 13, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Ulrich Brinkmann, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
-
Patent number: 9885704Abstract: The invention generally relates to the prevention and/or treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In one embodiment, the invention involves a method comprising: a) providing a subject with tumor cells, b) removing at least a portion of said tumor cells from said subject to create removed cells, c) treating at least a portion of said removed cells ex vivo, using stimulating agents, including thapsigargin and/or thapsigargin-related compounds, so as to create treated tumor cells; and d) introducing said treated tumor cells (or fragments thereof) in vivo into the same subject to generate anticancer therapeutic effects.Type: GrantFiled: July 15, 2015Date of Patent: February 6, 2018Assignee: The Buck Institute for Age ResearchInventors: Kayvan R. Niazi, Shahrooz Rabizadeh, Dale E. Bredesen
-
Patent number: 9873730Abstract: The present invention provides for a method for improving properties of an antibody such as an expression level and stability. A method for obtaining an antibody with an improved expression level and/or stability by modifying a human antibody or a humanized antibody, characterized by that at least any one of the amino acid residues at position 8, 12, 15 or 18 (according to Kabat numbering) in a light chain variable region (hereinafter referred to as “VL chain”) of a human antibody or a humanized antibody is substituted with a different amino acid other than proline or cysteine, and a human antibody or a humanized antibody or a human antibody fragment or a humanized antibody fragment with an improved expression level and/or stability which are obtained by said method.Type: GrantFiled: February 7, 2006Date of Patent: January 23, 2018Assignee: THE CHEMO-SERO-THERAPEUTIC RESERACH INSTITUTEInventors: Masaharu Torikai, Toshihiro Nakashima
-
Patent number: 9873747Abstract: Provided is a fusion protein comprising a polypeptide component that blocks binding of CD47 to SIRP alpha and a polypeptide that binds to and triggers a TRAIL receptor or Fas. Also provided is a method of treating cancer in a patient comprising administering the fusion protein of the invention to a patient in need of such treatment.Type: GrantFiled: January 31, 2014Date of Patent: January 23, 2018Assignee: Thomas Jefferson UniversityInventor: Mark L. Tykocinski
-
Patent number: 9869680Abstract: The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the Receptor Tyrosine-Protein Kinase erbB-3, or Her3 , that are particularly advantageous for quantifying the Her3 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.Type: GrantFiled: September 8, 2015Date of Patent: January 16, 2018Assignee: Expression Pathology, Inc.Inventors: David Krizman, Todd Hembrough, Sheeno Thyparambil
-
Patent number: 9862775Abstract: Provided is a monoclonal antibody which specifically recognizes B cell lymphoma cells and a use thereof. More specifically, provided are the monoclonal antibody; a pharmaceutical composition for preventing or treating B cell lymphoma including the monoclonal antibody; a composition for diagnosing B cell lymphoma including the monoclonal antibody; a method for providing information for diagnosing B cell lymphoma using the monoclonal antibody; a chimeric antigen receptor (CAR) protein including i) the antibody, ii) a transmembrane domain, and iii) an intracellular signaling domain; a recombinant vector which expresses the CAR protein; a CAR-modified T cell transformed with the recombinant vector; a pharmaceutical composition for preventing or treating B cell lymphoma including the CAR-modified T cell; and an antibody-drug conjugate wherein the monoclonal antibody and a drug are conjugated.Type: GrantFiled: March 5, 2015Date of Patent: January 9, 2018Assignee: Eutilex Co., Ltd.Inventors: Byoung Se Kwon, Kwang-Hui Kim, Young-Ho Kim, Ho-Sik Oh, Don-Gil Lee, Seung-Joo Lee, Beom-Kyu Choi, Insoo Park, Chungyong Han
-
Patent number: 9863935Abstract: Biomarkers are described for predicting the efficacy, risk of relapse, risk of an immune related adverse event (irAE), or combination thereof for a CTLA-4 blockade treatment, such as ipilimumab, in a subject with melanoma. Biomarkers are also described for predicting the efficacy and clinical benefit for a PD-1 blockade treatment, such as a PD-1 blocking antibody, in a subject with melanoma.Type: GrantFiled: March 15, 2013Date of Patent: January 9, 2018Assignee: H. Lee Moffitt Cancer and Research Institute, Inc.Inventors: Jeffrey S. Weber, Wenshi Wang, Bin Yu
-
Patent number: 9856319Abstract: Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: December 27, 2013Date of Patent: January 2, 2018Assignee: ABBVIE INC.Inventors: Tariq Ghayur, Jijie Gu
-
Patent number: 9850311Abstract: An isolated antibody that specifically binds to an extracellular domain of two or more human FZD receptors and inhibits growth of tumor cells is described. Also described is a method of treating cancer comprising administering an antibody of the present disclosure in an amount effective to inhibit tumor cell growth.Type: GrantFiled: October 31, 2006Date of Patent: December 26, 2017Assignee: ONCOMED PHARMACEUTICALS, INC.Inventors: Austin Gurney, John Lewicki, Sanjeev Satyal, Timothy Hoey
-
Patent number: 9845361Abstract: The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising said recognition molecules, methods for the production of said recognition molecules, and to the use of said recognition molecules in the diagnosis and therapy of tumor diseases.Type: GrantFiled: June 26, 2014Date of Patent: December 19, 2017Assignee: GLYCOTOPE GmbHInventors: Steffen Goletz, Antje Danielczyk, Renate Stahn, Uwe Karsten
-
Patent number: 9839681Abstract: This invention describes novel immunogenic complexes, which are designed to trigger a robust host immune response against cancer cells by co-opting the immune system's natural ability to eliminate pathogen-infected host cells. The immunogenic complexes, referred to as microbial mimetics (MM) have unique physical and biochemical properties, which are designed to simulate a pathogenic infection of similar sized bacteria and viruses, permitting tumor-associated and tumor-specific peptide antigens to be presented to immune cells as microbial constituents. The MM are well-suited to mimic a systemic infection with microbe sized particles comprised largely of tumor antigens. Under this framework, tumor cells may be eliminated in the ensuing immune response. The MM exhibit unique properties, including size tunability and contain antigenic cargo complexed to immune stimulatory molecules, which synergize to potentiate immune responses.Type: GrantFiled: June 27, 2017Date of Patent: December 12, 2017Inventor: Timothy Andrew Erickson
-
Patent number: 9834615Abstract: The invention provides novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule and methods for producing novel bispecific monoclonal antibodies carrying a different specificity for each binding site of the immunoglobulin molecule. The antibodies are composed of a single heavy chain and two different light chains, one containing a Kappa constant domain and the other of a Lambda constant domain. The invention provides methods for the isolation of antibodies of different specificities but sharing a common heavy chain. The invention also provides methods for the controlled co-expression of two light chains and a single heavy chain leading to the assembly of monospecific and bispecific antibodies.Type: GrantFiled: August 16, 2011Date of Patent: December 5, 2017Assignee: NOVIMMUNE SAInventors: Nicolas Fischer, Giovanni Magistrelli, Franck Gueneau, Ulla Ravn, Greg Elson
-
Patent number: 9833493Abstract: The present invention relates to a method for activating helper T cells, which includes the step of activating helper T cells by adding a WT1 peptide to antigen presenting cells, wherein the WT1 peptide has the ability to bind to an MHC class II molecule selected from HLA-DRB1*08:02 molecule, an HLA-DRB1*13:02 molecule, an HLA-DRB1*14:03 molecule, an HLA-DRB1*14:05 molecule, an HLA-DQB1*03:02 molecule, and an HLA-DQB1*04:01 molecule.Type: GrantFiled: December 16, 2013Date of Patent: December 5, 2017Assignee: International Institute of Cancer Immunology, Inc.Inventors: Hiroshi Kubo, Shinji Sogo, Haruo Sugiyama
-
Patent number: 9828438Abstract: The present invention provides dual specificity antibody fusion proteins comprising an antibody Fab or Fab? fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.Type: GrantFiled: July 6, 2016Date of Patent: November 28, 2017Assignee: UCB Pharma S.A.Inventors: David Paul Humphreys, Emma Dave, Laura Griffin, Sam Philip Heywood
-
Patent number: 9828590Abstract: Novel CARD-9, CARD-10, or CARD-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated CARD-9, CARD-10, or CARD-11 proteins, the invention further provides CARD-9, CARD-10, or CARD-11, fusion proteins, antigenic peptides and anti-CARD-9, CARD-10, or CARD-11 antibodies. The invention also provides CARD-9, CARD-10, or CARD-11 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a CARD-9, CARD-10, or CARD-11 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 17, 2015Date of Patent: November 28, 2017Assignee: Millennium Pharmaceuticals, Inc.Inventor: John Bertin